双向内皮质反驱动转向血管模式和药物耐药性利基:一项基于PDE代理的混合PDE研究
Zonghao Liu1, Louis Shuo Wang2, Jiguang Yu3,4
1Innovation Center for Cancer Research, Clinical Oncology School, Fujian Medical University, Fuzhou 350014, China.
Bioengineering (Basel, Switzerland)
|October 29, 2025
概括
这项研究引入了一种混合模型,将部分微分方程和基于代理的建模联系起来,以模拟瘤血管生成. 这些发现揭示了内皮细胞反如何创造血管模式,导致药物耐药性.
科学领域:
- 计算生物学 计算生物学
- 数学瘤学数学瘤学
- 生物物理学的生物物理.
背景情况:
- 瘤生长和治疗疗效受到瘤微环境异质性,特别是血管化的显著影响.
- 瘤的输液异质性导致氧气和药物分配变化,促进治疗耐药性.
- 了解瘤血管生成因子 (TAF) 和内皮细胞行为之间的相互作用对于开发有效疗法至关重要.
研究的目的:
- 开发和分析一个基于多尺度混合型偏微分方程代理模型 (PDE-ABM),集成瘤细胞,内皮细胞和分子信号.
- 研究内皮细胞的反机制,特别是TAF分泌和化学反应,如何驱动血管模式的形成.
- 确定影响血管异质性和药物透的关键参数,并提出减轻治疗耐药性的策略.
主要方法:
- 开发一个合的PDE-ABM框架,模拟TAF,氧和药物动态以及离散的内皮细胞和瘤细胞行为.
- 减少内皮-TAF反应-扩散子系统的线性稳定性分析,以确定图灵不稳定性的条件.
- 模拟新出现的血管模式,并评估它们对药物透和缺氧区域形成的影响.
主要成果:
- 沿TAF梯度的内皮细胞迁移和TAF分泌之间的双向合是必要的,并且足以产生空间周期性的血管集群.
- 这些新兴的血管模式创造了集群间的低氧区域,导致异质的药物透和耐药细胞的发展.
- 鉴定出TAF清除,化疗敏感性和内皮机动性是同质化瘤输液的关键参数.
结论:
- 混合PDE-ABM有效地捕捉了驱动瘤血管化和异质性的多尺度动态.
- 针对内皮-TAF反循环提供了一种潜在的策略,以改善药物输送和克服治疗耐药性.
- 这项研究为未来的3D扩展和定量临床应用的和动力学提供了基础.
关键词:
图灵不稳定性就是图灵的不稳定性.血管新生是因为血管新生.化学反应的化学作用.源自内皮的血管性反来自内皮.基于混合PDE剂的模型perfusion 不同质性的 perfusion 不同质性的药物动力学 药物动力学反应-扩散方程的反应-扩散方程.瘤药物耐药性 瘤药物耐药性瘤微环境是一个微环境.更多相关视频
09:39Development and Characterization of In Vitro Microvessel Network and Quantitative Measurements of Endothelial [Ca2+]i and Nitric Oxide Production
Published on: May 19, 2016
9.0K
07:41Author Spotlight: Automated Bioprinting for High-Throughput Vascular Model Fabrication
Published on: August 16, 2024
1.6K
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Mechanism of Angiogenesis
6.7K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.7K
Autoregulation of Blood Flow
7.4K
Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
7.4K
